PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16350494

A wee problem.

Mary Bishop
View original source ↗Export metadata ↓

Abstract

Stress incontinence plagues many women's lives. It is more common than diabetes or asthma, and can have major social and financial implications. Although treatment is available, new research suggests that women are often being given inappropriate drugs.

Explore related subjects

Adrenergic Uptake InhibitorsDuloxetine HydrochlorideFemaleHumansStress, PhysiologicalThiophenesUrinary IncontinenceJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Mary Bishop. A wee problem.. https://doi.org/10.7748/ns.20.12.20.s28

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Variable presentation of temporalis hypertrophy--A case report with literature review.

A case of painful, initially bilateral, and then unilateral temporalis hypertrophy in a 33-year-old Caucasian woman is presented in a primary care setting; the aetiology of the hypertrophy was considered reactive in nature. Medical and supportive treatment was successful in providing symptomatic relief. Further treatment including an intramuscular botulinum injection was considered by the patient with a view to reduction of the chronic enlargement of her temporalis and masseter musculature. A review of the literature and previous treatment regimes is also presented.

Adrenergic Uptake Inhibitors↗
PubMed2006

High-dose MDMA does not result in long-term changes in impulsivity in the rat.

RATIONALE: Evidence suggests that recreational users of (+/-)3,4-methylenedioxymethamphetamine HCl (MDMA, "ecstasy") have cognitive and behavioral deficits and show increased impulsivity consistent with 5-hydroxytryptamine (5-HT) neurotoxicity. MDMA effects on impulsivity in users are difficult to establish being confounded by polydrug use and individual predisposition to impulsivity or behavioral inhibition. OBJECTIVE: We previously observed a long-term anxiolytic effect of a neurotoxic dose of MDMA on elevated plus maze behavior in Dark Agouti (DA) rats while other strains were reported to show anxiogenesis. We have now examined whether MDMA influences impulsivity producing disinhibited behavior interpretable as anxiolysis. METHODS: Impulsivity was measured using an operant visuospatial discrimination procedure. Male DA rats (n = 24) were trained to lever press for food reward in response to a light-stimulus and subsequently required to withhold responding. Correct responses, premature responses, and response latencies were used as measures of accuracy and impulsivity. Trained rats were administered MDMA (5 mg/kg, i.p. at 3-h intervals to a total of three injections). Performance was measured at 3 h and 7, 27, 49, and 80 days posttreatment. RESULTS: There was a short-term effect of MDMA on the percentage of correct responses at 3 h and day 1 with recovery to control levels by days 7-8 and no significant long-term changes up to day 80. There was no effect of MDMA on premature responses on any of the days measured. MDMA reduced cortical 5-HT content (MDMA 363 +/- 14 ng/g and control 440 +/- 10 ng/g tissue). CONCLUSION: These results suggest that impulsivity may not be directly altered by MDMA despite serotonergic neurotoxicity.

Adrenergic Uptake Inhibitors↗
PubMed2006

Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder.

BACKGROUND: The cardiovascular safety of mixed amphetamine salts extended release (MAS XR) was evaluated in 2968 children 6-12 years of age with attention-deficit/hyperactivity disorder (ADHD). METHODS: In this prospective, open-label, noncomparative, community-based study, subjects whose symptoms of ADHD were well controlled with stimulant medication maintained their established treatment regimens for 2 weeks before enrollment into the current study. Subjects' regimens were then converted to an approximately equivalent once-daily dose of MAS XR 10, 20, or 30 mg/d according to a medication-conversion algorithm, which could be adjusted to 40 mg/d for optimal efficacy and tolerability. Systolic blood pressure (SBP), diastolic BP (DBP), and pulse were measured at each study visit. Twelve-lead electrocardiography was performed at screening and at the end of the extension phase or early termination. RESULTS: No clinically significant changes in BP or pulse were observed. Although one subject experienced a QT-prolongation interval > 25%, no clinically significant prolongation in the mean QT interval was seen. Approximately 2.5% of subjects demonstrated two consecutive SBP or DBP values > 95th percentile for age, sex, and height, and 3.6% of subjects' pulse increased by > or = 25 to > or = 110 beats per minute. No serious cardiovascular adverse events or deaths occurred. CONCLUSIONS: In addition to demonstrated efficacy and safety, the cardiovascular profile of MAS XR showed generally small divergences from age-specific population norms that pose very limited risk in this patient population.

Adrenergic Uptake Inhibitors↗